Denali Therapeutics
DNLI
203 hedge funds and large institutions have $3.18B invested in Denali Therapeutics in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 84 increasing their positions, 55 reducing their positions, and 25 closing their positions.
196% more call options, than puts
Call options by funds: $1.23M | Put options by funds: $416K
53% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 55
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
28% more capital invested
Capital invested by funds: $2.49B → $3.18B (+$694M)
8% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 25
0% more funds holding
Funds holding: 202 → 203 (+1)
0.17% less ownership
Funds ownership: 79.04% → 78.86% (-0.17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$51.7M |
| 2 |
BlackRock
New York
|
+$17.8M |
| 3 |
Morgan Stanley
New York
|
+$14.3M |
| 4 |
Man Group
London,
United Kingdom
|
+$14.2M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$14.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$52.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$37.1M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$14.3M |
| 4 |
Barclays
London,
United Kingdom
|
-$14M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$10.9M |
DNLI Hedge Fund Activity: Q2 2023 in Review
203 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q2 2023, worth a combined $3.18B — up 28% from $2.49B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new DNLI positions and 25 closed out — a net gain of 2 holders — while 84 added to existing stakes and 55 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $51.7M. The largest seller was Arch Venture Management, cutting an estimated $52.7M.
- 203 institutional investors held Denali Therapeutics (DNLI) as of Q2 2023, up from 202 in Q1 2023.
- Funds reported $3.18B of Denali Therapeutics stock for Q2 2023, up 28% quarter-over-quarter.
- 27 funds opened new Denali Therapeutics positions in Q2 2023 and 25 closed out, a net change of +2 holders.
- The largest Denali Therapeutics buyer in Q2 2023 was Wellington Management Group, an estimated $51.7M added.
- The largest Denali Therapeutics seller in Q2 2023 was Arch Venture Management, an estimated $52.7M sold.
Based on aggregated 13F filings for Q2 2023.